1. Weiner HL, et al. Oral tolerance Immunol Rev 2011;241:241-59.
2. Egan RM, et al. In Vivo Behavior of Peptide-Specific T Cells During Mucosal Tolerance Induction: Antigen Introduced Through the Mucosa of the Conjunctiva Elicits Prolonged Antigen-Specific T Cell Priming Followed by Anergy. J Immunol 2000;164:4543-50.
3. Chen Y, et al. Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature 1995;376:177-80.
4. Tsuji NM, et al. Interleukin-10-secreting Peyer's patch cells are responsible for active suppression in low-dose oral tolerance. Immunology 2001;103:458-64.
5. Burks AW, et al. Oral tolerance, food allergy, and immunotherapy: implications for future treatment. J Allergy Clin Immunol 2008;121:1344-50.
6. 海老濹 元宏ら.AMED 研究班による食物アレルギー診療の手引き 2017 (2017)
7. Bufe A, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol. 2009;123:167-73.
8. Didier A, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5–grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007;120:1338-45.
9. Calderón MA, et al. Guideline recommendations on the use of allergen immunotherapy in house dust mite allergy: Time for a change? J Allergy Clin Immunol 2017;140:41-52.
10. Sturm GJ, et al. EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy. Allergy 2018;73:744-64.
11. Buchanan AD, et al. Egg oral immunotherapy in nonanaphylactic children with egg allergy. J Allergy Clin Immunol 2007;119:199-205.
12. Skripak JM et al. A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy. J Allergy Clin Immunol 2008;122:1154-60.
13. Nurmatov U, et al. Allergen immunotherapy for IgE-mediated food allergy: a systematic review and meta-analysis. Allergy 2017;72:1133-47.
14. Meglio P, et al. A protocol for oral desensitization in children with IgE-mediated cow’s milk allergy. Allergy 2004;59:980-87.
15. Patriarca G, et al. Oral desensitizing treatment in food allergy: clinical and immunological results. Aliment Pharmacol Ther 2003;17:459-65.
16. Watanabe H, et al. Heat treatment of egg white controls allergic symptoms and induces oral tolerance to ovalbumin in a murine model of food allergy. Mol Nutr Food Res. 2014;58:394-404.
17. Hiraide E, et al. Oral Administration of T Cell Epitope Peptide Inhibits the Systemic IL-4 Response Elicited by an Egg-White Diet in a TCR Transgenic Mouse Model. Biosci Microbiota Food Health 2014;33:47-51.
18. Curin M, et al. Single recombinant and purified major allergens and peptides: How they are made and how they change allergy diagnosis and treatment. Ann Allergy Asthma Immunol 2017;119:201-9.
19. Lanier B, et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol 2009;124:1351-2.
20. Blumchen K, et al. Oral peanut immunotherapy in children with peanut anaphylaxis. J Allergy Clin Immunol 2010;126:83-91.
21. Lucendo AJ, et al. Relation between eosinophilic esophagitis and oral immunotherapy for food allergy: a systematic review with meta-analysis. Ann Allergy Asthma Immunol 2014;113:624-9.
22. Virkud YV, et al. Novel baseline predictors of adverse events during oral immunotherapy in children with peanut allergy. J Allergy Clin Immunol 2017;139:882-8.
23. Eberlein-König B, et al. Tryptase and histamine release due to a sting challenge in bee venom allergic patients treated successfully or unsuccessfully with hyposensitization. Clin. and Exp. Allergy 1995;25:704-12.
24. Plewako H, et al. Basophil Interleukin 4 and Interleukin 13 Production Is Suppressed during the Early Phase of Rush Immunotherapy. Int Arch Allergy Immunol 2006;141:346-53.
25. Celensnic N, et al. Short-term venom immunotherapy induces desensitization of FceRI-mediated basophil response. Allergy 2012;67:1594-1600.
26. James NF, et al. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003;111:1255-61.
27. Jutel, M, et al. IL-10 and TGF-β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003;33:1205-14.
28. Radulovic S, et al. Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol. 2008;121:1467-72.
29. van de Veen W, et al. IgG4 production is confined to human IL-10–producing regulatory B cells that suppress antigen-specific immune responses. J Allergy Clin Immunol 2013;131:1204-12.
30. Meiler F, et al. Distinct regulation of IgE, IgG4 and IgA by T regulatory cells and toll-like receptors. Allergy 2008;63:1455-63.
31. Möbs C, et al. Birch pollen immunotherapy results in long-term loss of Bet v 1– specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies. J Allergy Clin Immunol 2012;130:1108-16.
32. Kayhan T, et al. Grass Pollen Immunotherapy Induces Mucosal and Peripheral IL-10 Responses and Blocking IgG Activity. J Immunol 2004;172:3252-59.
33. 中尾篤人. アレルゲン免疫療法の作用機序の基礎アレルギー・免疫 2014:21:1044-49.
34. Mübeccel A et al. Mechanisms of allergen-specific immunotherapy: Multiple suppressor factors at work in immune tolerance to allergens. J Allergy Clin Immunol 2014;133:621-31.
35. 大塚篤司.バリア総論 アレルギー・免疫 2017;24:716-22.
36. Lack G, et al. Epidermiologic risks for food allergy. J Allergy Clin Immunol. 2008;121:1331-36.
37. Kobayashi T, et al. Eighteen cases of wheat allergy and wheat-dependent exercise-induced urticaria/anaphylaxis sensitized by hydrolyzed wheat protein in soap. Int J Dermatol 2015;54:e302-5.
38. Fukutomi Y, et al. Epidemiological link between wheat allergy and exposure to hydrolyzed wheat protein in facial soap. Allergy 2014;69:1405-11.
39. 善本知広. 経皮感作食物アレルギーの分子メカニズム:二重抗原曝露仮説の実験的エビデンス アレルギー 2017;66:1224-29.
40. Basophils are required for the induction of Th2 immunity to haptens and peptide antigens. Nat Commun 2013;4:1738.
41. Yoshimoto T, et al. Basophils contribute to T(H)2-IgE responses in vivo via IL-4 production and presentation of peptide-MHC class II complexes to CD4+ T cells. Nat Immunol 2009;10:706-12.
42. Muto T, et al. The role of basophils and proallergic cytokines, TSLP and IL-33, in cutaneously sensitized food allergy. Int Immunol 2014;26:539-49.
43. Haenuki Y, et al. A critical role of IL-33 in experimental allergic rhinitis. J Allergy Clin Immunol 2012;130:184-94.e11
44. Senti G, et al. Determinants of efficacy and safety in epicutaneous allergen immunotherapy: summary of three clinical trials. Allergy 2015;70:707-10.
45. Sampson HA, et al. Effect of Varying Doses of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Exposure Among Patients With Peanut Sensitivity: A Randomized Clinical Trial. JAMA 2017;318:1798-1809.
46. Mondoulet L, et al. Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy. Clin Exp Allergy 2010;40:659-67.
47. Mondoulet L, et al. Epicutaneous immunotherapy using a new epicutaneous delivery system in mice sensitized to peanuts. Int Arch Allergy Immunol 2011;154:299-309.
48. Dioszeghy V, et al. Epicutaneous immunotherapy results in rapid allergen uptake by dendritic cells through intact skin and downregulates the allergen-specific response in sensitized mice. J Immunol 2011;186:5629-37.
49. Mondoulet L, et al. Epicutaneous immunotherapy (EPIT) blocks the allergic esophago-gastro-enteropathy induced by sustained oral exposure to peanuts in sensitized mice. PLoS One 2012;7:e31967.
50. Mondoulet L, et al. Intact skin and not stripped skin is crucial for the safety and efficacy of peanut epicutaneous immunotherapy (EPIT) in mice. Clin Transl Allergy 2012;2:22.
51. Dioszeghy V, et al. The regulatory T cells induction by epicutaneous immunotherapy is sustained and mediates long-term protection from eosinophilic disorders in peanut-sensitized mice. Clin Exp Allergy 2014;44:867-81.
52. Mondoulet L, et al. Specific epicutaneous immunotherapy prevents sensitization to new allergens in a murine model. J Allergy Clin Immunol 2015;135:1546-57.e4.
53. Dioszeghy V, et al. Differences in phenotype, homing properties and suppressive activities of regulatory T cells induced by epicutaneous, oral or sublingual immunotherapy in mice sensitized to peanut. Cell Mol Immunol 2017;14:770-82.
54. Tordesillas L, et al. Epicutaneous immunotherapy induces gastrointestinal LAP+ regulatory T cells and prevents food-induced anaphylaxis. J Allergy Clin Immunol 2017;139:189-201.e4.
55. Mondoulet L, et al. Gata3 hypermethylation and Foxp3 hypomethylation are associated with sustained protection and bystander effect following epicutaneous immunotherapy in peanut-sensitized mice. Allergy 2018 May 19. doi: 10.1111/all.13479. [Epub ahead of print]
56. Matsuo K, et al. Analysis of transcutaneous antigenic protein delivery by a hydrogel patch formulation. J Pharm Sci 2013;102:1936-47
57. Kitaoka M, et al. Transcutaneous Peptide Immunotherapy of Japanese Cedar Pollinosis Using Solid-in-Oil Nanodispersion Technology. AAPS PharmSciTech 2015;16:1418-24.
58. Kitaoka M, et al. Solid-in-oil nanodispersions for transdermal drug delivery systems. Biotechnol J 2016;11:1375-85.
59. von Moos S, et al. The contact sensitizer diphenylcyclopropenone has adjuvant properties in mice and potential application in epicutaneous immunotherapy. Allergy 2012;67:638-46.
60. Scheurer S, et al. Epicutaneous immunotherapy. Allergol Immunopathol 2017;4551:25-9.
61. Senti G, et al. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J Allergy Clin Immunol 2009;124:997-1002.
62. Wang J, et al. Safety and efficacy of epicutaneous immunotherapy for food allergy. Pediatr Allergy Immunol 2018;29:341-49.
63. Teijeira A, et al. T Cell Migration from Inflamed Skin to Draining Lymph Nodes Requires Intralymphatic Crawling Supported by ICAM-1/LFA-1 Interactions. Cell Rep 2017;18:857-65.
64. Lämmermann T, et al. The microanatomy of T-cell responses. Immunol Rev 2008;221:26-43.
65. Reinhardt RL, et al. Visualizing the generation of memory CD4 T cells in the whole body. Nature 2001;410:101-5.
66. Masopust D, et al. Preferential localization of effector memory cells in nonlymphoid tissue. Science 2001;291:2413-7.
67. Austrup F, et al. P- and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into inflammed tissues. Nature 1997;385:81-3.
68. Reinhardt RL, et al. Preferential Accumulation of Antigen-specific Effector CD4 T Cells at an Antigen Injection Site Involves CD62E-dependent Migration but Not Local Proliferation. J Exp Med 2003;197:751-62.
69. Mueller DL, et al. Mechanisms maintaining peripheral tolerance. Nat Immunol 2010;11:21-7.
70. Mora JR, et al. T-cell homing specificity and plasticity: new concepts and future challenges. Trends Immunol 2006;27:235-43.,
71. Sigmundsdottir H, et al. Environmental cues, dendritic cells and the programming of tissue-selective lymphocyte trafficking. Nat Immunol 2008;9:981-7.
72. Woodland DL, et al. Migration, maintenance and recall of memory T cells in peripheral tissues. Nat Rev Immunol 2009;9:153-61.
73. Lindblad EB, et al. Aluminium compounds for use in vaccines. Immunol Cell Biol 2004;82:497-505.
74. Harrison WT, et al. Some observations on the use of alum precipitated diphtheria toxid. Am J Public Health Nations Health 1935;25:298.
75. Schnare M, et al. Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2001;2:947-50.
76. Gavin AL, et al. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 2006;314:1936-38.
77. Brewer JM, et al. Aluminium Hydroxide Adjuvant Initiates Strong Antigen-Specific Th2 Responses in the Absence of IL-4- or IL-13-Mediated Signaling. J Immunol 1999;163:6448-54.
78. Jordan MB, et al. Promotion of B Cell Immune Responses via an Alum-Induced Myeloid Cell Population. Science 2004;304:1808-10.
79. Wang HB, et al. Pivotal advance: eosinophils mediate early alum adjuvant-elicited B cell priming and IgM production. J Leukoc Biol 2008;83:817-21.
80. McKee AS, et al. Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J Immunol 2009;183:4403-14.
81. Hornung V, et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 2008;9:847-56.
82. Eisenbarth SC, et al. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008;453:1122-6.
83. Li H, et al. Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J Immunol 2008;181:17-21.
84. Franchi L, et al. The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity. Eur J Immunol 2008;38:2085-9.
85. Kool M, et al. Alum Adjuvant Stimulates Inflammatory Dendritic Cells through Activation of the NALP3 Inflammasome. J Immunol 2008;181:3755-9.
86. Shi Y, et al. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003;425:516-21.
87. Kool M, et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 2008;205:869-82.
88. Kool M, et al. An unexpected role for uric acid as an inducer of T helper 2 cell immunity to inhaled antigens and inflammatory mediator of allergic asthma. Immunity 2011;34:527-40.
89. Marichal T, et al. DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med 2011;17:996-1002.
90. McKee AS, et al. Host DNA released in response to aluminum adjuvant enhances MHC class II-mediated antigen presentation and prolongs CD4 T-cell interactions with dendritic cells. Proc Natl Acad Sci U S A 2013;110:E1122-31.
91. Flach TL, et al. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat Med 2011;17:479-87.
92. Wu LC, et al. The production and regulation of IgE by the immune system. Nat Rev Immunol 2014;14:247-59.
93. 羽生田圭 ほか、IgE産生の制御機構 臨床免疫・アレルギー科 2017:67:506-12.
94. Vijayanand P, et al. Interleukin-4 production by follicular helper T cells requires the conserved Il4 enhancer hypersensitivity site V. Immunity 2012;36:175-87.
95. Harada Y, et al. The 3' enhancer CNS2 is a critical regulator of interleukin-4-mediated humoral immunity in follicular helper T cells. Immunity 2012;36:188-200.
96. Ozaki K, et al. A critical role for IL-21 in regulating immunoglobulin production. Science 2002;298:1630-34.
97. Weinstein JS, et al. TFH cells progressively differentiate to regulate the germinal center response. Nat Immunol 2016;17:1197-1205.
98. Martin RK, et al. Antigen transfer from exosomes to dendritic cells as an explanation for the immune enhancement seen by IgE immune complexes. PLoS One 2014;9:e110609.
99. Haniuda K, et al. Autonomous membrane IgE signaling prevents IgE-memory formation. Nat Immunol 2016;17:1109-17.
100. Daëron M, et al. Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. J Clin Invest 1995;95:577-85.
101. Uermösi C, et al. IgG-mediated down-regulation of IgE bound to mast cells: a potential novel mechanism of allergen-specific desensitization. Allergy 2014;69:338-47.
102. Nakajima-Adachi H, et al. Peyer's patches and mesenteric lymph nodes cooperatively promote enteropathy in a mouse model of food allergy. PLoS One 2014;9:e107492.
103. Nakajima-Adachi H, et al. Critical role of intestinal interleukin-4 modulating regulatory T cells for desensitization, tolerance, and inflammation of food allergy. PLoS One 2017;12:e0172795.
104. Aoki-Yoshida A, et al. Enhancement of Oral Tolerance Induction in DO11.10 Mice by Lactobacillus gasseri OLL2809 via Increase of Effector Regulatory T Cells. PLoS One 2016;11:e0158643.
105. Shibahara K, et al. Food Allergen-induced IgE Response Mouse Model Created by Injection of in vitro Differentiated Th2 Cell Culture and Oral Antigen Intake. Biosci Microbiota Food Health 2014;33:41-6.
106. Burggraf M, et al. Oral tolerance induction does not resolve gastrointestinal inflammation in a mouse model of food allergy. Mol Nutr Food Res 2011;55:1475-83.
107. Hiraide E, et al. Oral administration of ovalbumin after sensitization attenuates symptoms in a mouse model of food allergic enteropathy. Biosci Biotechnol Biochem. 2017;81:1967-72.
108. Ito T, et al. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J Exp Med 2005;202:1213-23.
109. Ebner S, et al. Thymic stromal lymphopoietin converts human epidermal Langerhans cells into antigen-presenting cells that induce proallergic T cells. J Allergy Clin Immunol 2007;119:982-90.
110. Hussain M, et al. Basophil-derived IL-4 promotes epicutaneous antigen sensitization concomitant with the development of food allergy. J Allergy Clin Immunol 2018;141:223-34.e5
111. Nakahashi-Oda C, et al. Apoptotic epithelial cells control the abundance of Treg cells at barrier surfaces. Nat Immunol 2016;17:441-50.
112. Suárez-Fariñas M, et al. Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J Allergy Clin Immunol 2011;127:954-64.
113. Gittler JK, et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol 2012;130:1344-54.
114. Rochman Y, et al. TSLP signaling in CD4+ T cells programs a pathogenic T helper 2 cell state. Sci Signal 2018;11:eaam8858.
115. Tomura M, et al. Tracking and quantification of dendritic cell migration and antigen trafficking between the skin and lymph nodes. Sci Rep 2014;4:6030.
116. Komatsu N, et al. Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc Natl Acad Sci USA 2009;106:1903-8.
117. Nakanishi Y, et al. Regulatory T cells with superior immunosuppressive capacity emigrate from the inflamed colon to draining lymph nodes. Mucosal Immunol 2018;11:437-448.
118. Nakajima-Adachi H, et al. Food antigen causes TH2-dependent enteropathy followed by tissue repair in T-cell receptor transgenic mice. J Allergy Clin Immunol 2006;117:1125-32.
119. 芝原恭子。抗原の経口摂取によって誘導されるT細胞応答に関する研究 東京大学 博士論文 2016
120. Miller MJ, et al. Two-photon imaging of lymphocyte motility and antigen response in intact lymph node. Science 2002;296:1869-73.
121. Katakai T, et al. Dendritic cells regulate high-speed interstitial T cell migration in the lymph node via LFA-1/ICAM-1. J Immunol 2013;191:1188-99.
122. Katakai T, et al. Autotaxin produced by stromal cells promotes LFA-1-independent and Rho-dependent interstitial T cell motility in the lymph node paracortex. J Immunol 2014;193:617-26.
123. Rosenblum MD, et al. Regulatory T cell memory. Nat Rev Immunol 2016;16:90-101.
124. Chalermsarp N, et al. Identification of three distinct subsets of migrating dendritic cells from oral mucosa within the regional lymph nodes. Immunology 2009;127:558-66.
125. Zhang C, et al. Repeated antigen painting and sublingual immunotherapy in mice convert sublingual dendritic cell subsets. Vaccine 2014;32:5669-76
126. Mascarell L, et al. Oral macrophage-like cells play a key role in tolerance induction following sublingual immunotherapy of asthmatic mice. Mucosal Immunol 2011;4:638-47.
127. Natsuaki Y, et al. Perivascular leukocyte clusters are essential for efficient activation of effector T cells in the skin. Nat Immunol 2014;15:1064-9.
128. Tordesillas L, et al. Skin exposure promotes a Th2-dependent sensitization to peanut allergens. J Clin Invest 2014;124:4965-75.
129. Tu E, et al. T Cell Receptor-Regulated TGF-β Type I Receptor Expression Determines T Cell Quiescence and Activation. Immunity 2018;48:745-759.
130. 森永真実子.免疫療法に向けたアレルゲン経口・経皮投与の食物アレルギーモデルへの影響の解析 東京大学 修士論文 2016
131. Liu XY, et al. Forkhead box protein-3 (Foxp3)-producing dendritic cells suppress allergic response. Allergy 2017;72:908-917.
132. 平出恵利華、食物アレルギー反応の制御を目的としたモデルマウスにおける免疫細胞の動態解析 東京大学 博士論文 2015